Clinical analysis of transcatheter closure of perimembranous ventricular septal defects with occluders made in China

被引:12
作者
Li Xin [2 ]
Li Ling [2 ]
Wang Xian [1 ]
Zhao Huai-bing [1 ]
Zhang Shou-yan [1 ]
机构
[1] Mil Gen Hosp Beijing, Dept Cardiol, Beijing 100700, Peoples R China
[2] Zhengzhou Univ, Dept Cardiol, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China
关键词
transcatheter; closure; ventricular septal defect; perimembranous ventricular septal defect; MEMBRANOUS VSD OCCLUDER; PRELIMINARY EXPERIENCE; DEVICE CLOSURE; IMMEDIATE; OCCLUSION; BLOCK;
D O I
10.3760/cma.j.issn.0366-6999.2011.14.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Results of perimembranous ventricular septal defects (pmVSD) transcatheter closure have been reported in the literature mostly using a Amplatzer VSD device. However, the data of percutaneous closure of pmVSD with VSD occluder (VSD-O) made in China are still limited. We sought to analyze safety, efficacy, and follow-up results of percutaneous closure of pmVSD with VSD-O made in China. Methods Between February 2005 and June 2009, 78 patients underwent percutaneous closure of pmVSD at our institution. A VSD device made in China was used for all subjects. The safety and the efficacy of the VSD-O were investigated. Results The average age at closure was 11 years (range 2.5 to 44 years). The attempt to place device was successful in 74 patients (94.9%). The average device size used was 8 mm (range 5 to 16 mm). No deaths occurred. Total occlusion rate was 62.8% at completion of the procedure, rising up to 87.2% at discharge and 99.0% during follow-up. A total of eight early complications occurred (10.3%), but in all subjects these were transient. The average follow-up period was 40.5 months. The most significant complication was complete atrioventricular block (cAVB) in the early phase (five subjects, 6.4%) and during the follow-up (1 subject, 1.3%), which saw no need for pacemaker implantation in six subjects. Cox proportional hazards regression analysis showed that the age was only the variable significantly associated with the occurrence of this complication during the procedure (P=0.025; relative risk 0.22). The subjects who experienced this complication were less than five years old. Conclusions Percutaneous pmVSD closure used VSD-O made in China is associated with excellent success and closure rates, no mortality, and low morbidity. Longer follow-up data and improvements in device characteristics are needed to reduce the risk of cAVB. Chin Med J 2011;124(14):2117-2122
引用
收藏
页码:2117 / 2122
页数:6
相关论文
共 20 条
[1]  
Arora Ramesh, 2003, J Interv Cardiol, V16, P83, DOI 10.1046/j.1540-8183.2003.08006.x
[2]   Initial human experience with the Amplatzer perimembranous ventricular septal occluder device [J].
Bass, JL ;
Kalra, GS ;
Arora, R ;
Masura, J ;
Gavora, P ;
Thanopoulos, BD ;
Torres, W ;
Sievert, H ;
Carminati, M ;
Fischer, G ;
Ewert, P .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (02) :238-245
[3]   Percutaneous versus surgical closure of secundum atrial septal defect:: Comparison of early results and complications [J].
Butera, G ;
Carminati, M ;
Chessa, M ;
Youssef, R ;
Drago, M ;
Giamberti, A ;
Pomè, G ;
Bossone, E ;
Frigiola, A .
AMERICAN HEART JOURNAL, 2006, 151 (01) :228-234
[4]   Transcatheter closure of perimembranous ventricular septal defects - Early and long-term results [J].
Butera, Gianfranco ;
Carminati, Mario ;
Chessa, Massimo ;
Piazza, Luciane ;
Micheletti, Angelo ;
Negura, Diana Gabriella ;
Abella, Raul ;
Giamberti, Alessandro ;
Frigiola, Alessandro .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (12) :1189-1195
[5]   Transcatheter closure of congenital ventricular septal defect with amplatzer septal occluders [J].
Carminati, M ;
Butera, G ;
Chessa, M ;
Drago, M ;
Negura, D ;
Piazza, L .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (12A) :52L-58L
[6]   Early and late complications associated with transcatheter occlusion of secundum atrial septal defect [J].
Chessa, M ;
Carminati, M ;
Butera, G ;
Bini, RM ;
Drago, M ;
Rosti, L ;
Giamberti, A ;
Pomè, G ;
Bossone, E ;
Frigiola, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (06) :1061-1065
[7]   Transcatheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder - Results of the US phase I trial [J].
Fu, YC ;
Bass, J ;
Amin, Z ;
Radtke, W ;
Cheatham, JP ;
Hellenbrand, WE ;
Balzer, D ;
Cao, QL ;
Hijazi, ZM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) :319-325
[8]   Device closure of ventricular septal defects [J].
Hijazi, ZM .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 60 (01) :107-114
[9]   Catheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder: Initial clinical experience [J].
Hijazi, ZM ;
Hakim, F ;
Abu Haweleh, A ;
Madani, A ;
Tarawna, W ;
Hiari, A ;
Cao, OL .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 56 (04) :508-515
[10]   Device closure of muscular ventricular septal defects using the amplatzer muscular ventricular septal defect occluder - Immediate and mid-term results of a US registry [J].
Holzer, R ;
Balzer, D ;
Cao, QL ;
Lock, K ;
Hijazi, ZM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (07) :1257-1263